Swine flu: vaccinations

The multinational pharmaceutical companies which are supplying the swine flu vaccine in Ireland insisted on an "unlimited" government indemnity against any possible adverse side effects.


In their negotiations with the government, Baxter International and GlaxoSmithKline (GSK) both stipulated that provision of the indemnity by the state would be necessary before they would agree to include Ireland on the list of states to receive the vaccine first.


The controversial move could leave the taxpayer facing a potential multimillion-euro compensation bill in the coming years should any problems emerge in relation to the H1N1 vaccine.


A spokeswoman for the Department of Health said to put an "advance purchase agreement" in place, it was necessary for the state to provide the indemnity.


"There would have been no guarantee of early supplies of the vaccine if the advance purchase agreement had not been put in place," she said. "Only countries which have the advance purchase agreement in place were guaranteed early supplies of a pandemic vaccine.


"In the context of licences being granted on the basis of a 'mock-up' vaccine without the usual clinical trials of the vaccine being undertaken, Ireland was, in common with other countries, required to give an indemnity to vaccine manufacturers."


Spokespeople for both compan­ies declined to comment on the details of the contracts. A spokeswoman for GSK said, "The industry has worked together with governments to 'appropriately allocate' potential liability during the extenuating circumstances of H1N1 mass vaccination.